N/A N=1,881 Impact of Diet on Functional Gastrointestinal Symptoms
Gastrointestinal Disorder, Functional
Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
N/A N=158 Clinical Improvement and in Quality of Life-Functional Dyspepsia-
Psychogenic Dyspepsia
Primary: Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS) — 73.72; 65.31; 71.85; 64.89 units on a scale
Phase 2 N=20 Effect of Secretin in Functional Dyspepsia and Healthy Subjects
Dyspepsia · Healthy
Primary: Maximum Satiation — 892.5; 951.75; 655.5; 892.5 mL — p=0.12
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
N/A N=23 Functional Dyspepsia Hypnosis
Functional Dyspepsia
Primary: Percent of Participants That Complete the Hypnotherapy Program — 22 Participants
N/A N=99 Fear, Gastrointestinal Distress, and Interoception: Physiological and Psychological Mechanisms in Eating Disorders
Feeding and Eating Disorders
Primary: Subjective Rating of Fear — -36.9444; -23.9219; -47.3611; 85.6250 units on scale*minutes — p=.879
Phase 4 N=74 A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
Irritable Bowel Syndrome
Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78
N/A N=33 Systematic Pediatric Assessment of Rome Criteria (SPARC)
Functional Gastrointestinal Disorders
Primary: Resolution of Symptoms From Initial Rome IV Diagnosis at 3 Months Using an Age-appropriate Rome IV Questionnaire. Number of Participants Who no Longer Meet Rome IV…
N/A N=10 Buspirone for Functional Dysphagia
Functional Dysphagia · Ineffective Esophageal Motility
Primary: Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry — 241.9; 340.4 mm Hg
Phase 2 N=104 Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
Dyspepsia · Diabetes Mellitus With Gastrointestinal Symptoms
Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
N/A N=31 Efficacy of Open Label Placebo in Children With FGIDs
Functional Abdominal Pain · Functional Dyspepsia · Irritable Bowel Syndrome
Primary: The Primary Outcome Measure Was Mean Daily Pain — 39.9; 45.14 pain scale by VAS in mm — p=<0.03
N/A N=48 Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Lactulose Mannitol Excretion — 512.5; 394.5; 456.8; 411 micrograms per ml
Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
N/A N=29 Dietary Triggers of Gastrointestinal Symptoms in IBS Patients
Irritable Bowel Syndrome
Primary: Number of Participants With Worsening Irritable Bowel Syndrome (IBS) Symptoms Based on IBS-SSS — 8; 10; 11 Participants
Phase 4 N=262 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia
Dyspepsia · Compliance · Depression
Primary: Compliance of Flupentixol-Melitracen — 44; 28; 31 participants
N/A N=7 Physiology of GERD and Treatment Response
GERD
Primary: Change in GERD Symptoms — 0.6; -1.7 units on a scale — p=0.41
N/A N=11 Behavioral Therapy in Patients With Rumination
Functional Gastrointestinal Disorders
Primary: Rumination Score (Self-perceived Rumination Frequency) — 4 score on a scale — p=0.005
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
N/A N=110 Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia
Fibromyalgia · Gastrointestinal Disease
Primary: Change, From Baseline to Endpoint (12 Weeks) in the Composite Score of Abdominal Pain, Abdominal Bloating and Metheorism Each One Measured in a 0-10 Visual Analog Scale…
N/A N=436 Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Clinical Global Impressions - Improvement Scale (CGI-I; Patient Version) — 68.1; 64.6; 46.7; 64.0 percentage of treatment responders
N/A N=225 Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
Irritable Bowel Syndrome · Colitis, Ulcerative · Crohn Disease
Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population
N/A N=48 Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
N/A N=17 Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)
Diarrhea Predominant Irritable Bowel Syndrome
Primary: Number of Subjects Reporting "Adequate Relief" From IBS Symptoms for the Previous Week. Adequate Relief Was a "True/False" Item. — 13 Participants
N/A N=25 Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder
Functional Bowel Disorders
Primary: Adequate Relief in Pain Score During Treatment — 52.6 percentage of subjects
Phase 3 N=224 B. Lactis HN019 for Functional Constipation
Constipation
Primary: Whole Gut Transit Time
N/A N=30 Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Conversion Disorder
Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score
N/A N=54 Gulf War Digestive Health Study
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours